Cargando…

In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus Associated with Skin and Soft Tissue Infections

Skin and soft tissue infections (SSTIs) are associated with significant morbidity and healthcare costs, especially when caused by methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin is a preferred antimicrobial therapy for the management of complicated SSTIs (cSSTIs) caused by MRSA, with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maraki, Sofia, Mavromanolaki, Viktoria Eirini, Stafylaki, Dimitra, Iliaki-Giannakoudaki, Evangelia, Hamilos, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215806/ https://www.ncbi.nlm.nih.gov/pubmed/37237803 http://dx.doi.org/10.3390/antibiotics12050900

Ejemplares similares

The Evolving Epidemiology of Serotype Distribution and Antimicrobial Resistance of Streptococcus pneumoniae Strains Isolated from Adults in Crete, Greece, 2009–2016
por: Maraki, Sofia, et al.
Publicado: (2018)

In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
por: Binyamin, Dana, et al.
Publicado: (2018)

Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia
por: Barber, Katie E., et al.
Publicado: (2017)

Synergistic Combinations of FDA-Approved Drugs with Ceftobiprole against Methicillin-Resistant Staphylococcus aureus
por: Sharma, Amar Deep, et al.
Publicado: (2022)

Dalbavancin Boosts the Ability of Neutrophils to Fight Methicillin-Resistant Staphylococcus aureus
por: Scutera, Sara, et al.
Publicado: (2023)

Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)
por: Knafl, D., et al.
Publicado: (2016)

In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid
por: Vanegas Múnera, Johanna Marcela, et al.
Publicado: (2017)

Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitive Staphylococcus Aureus
por: Hoyt, Aaron K., et al.
Publicado: (2023)

712. Identification of a Novel Tedizolid Resistance Mutation in rpoB of Methicillin-Resistant Staphylococcus aureus
por: Werth, Brian, et al.
Publicado: (2018)

Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model
por: Kussmann, Manuel, et al.
Publicado: (2018)

Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report
por: Otero, Judith Álvarez, et al.
Publicado: (2019)

Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections
por: Sivori, Francesca, et al.
Publicado: (2022)

Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole
por: Mendes, Rodrigo E., et al.
Publicado: (2016)

Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet?
por: Mahatanan, Rattanaporn, et al.
Publicado: (2023)

A 5-year Surveillance Study on Antimicrobial Resistance of Acinetobacter baumannii Clinical Isolates from a Tertiary Greek Hospital
por: Maraki, Sofia, et al.
Publicado: (2016)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Dalbavancin Alone and in Combination with Ceftaroline against Methicillin-Resistant Strains (MRSA) of Staphylococcus aureus
por: Kebriaei, Razieh, et al.
Publicado: (2017)

Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report
por: Almangour, Thamer A., et al.
Publicado: (2017)

Dalbavancin was effective and safe after one year of treatment in a complicated osteoarticular infection caused by methicillin-resistant Staphylococcus aureus
por: Matesanz, Mayra, et al.
Publicado: (2021)

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus: A Retrospective Single-Centre Experience
por: Mazzitelli, Maria, et al.
Publicado: (2022)

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

In vitro additive effects of dalbavancin and rifampicin against biofilm of Staphylococcus aureus
por: Jacob, Benjamin, et al.
Publicado: (2021)

Examining the Prevalence and Antibiotic Susceptibility of S. aureus Strains in Hospitals: An Analysis of the pvl Gene and Its Co-Occurrence with Other Virulence Factors
por: Vittorakis, Eftychios, et al.
Publicado: (2023)

Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections
por: Molina, Kyle C, et al.
Publicado: (2022)

Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm
por: Gidari, Anna, et al.
Publicado: (2020)

Ceftobiprole medocaril
por: Méndez, Raúl, et al.
Publicado: (2022)

2129. When Is Methicillin-resistant Staphylococcus aureus not Methicillin-resistant Staphylococcus aureus?
por: Gitman, Melissa R, et al.
Publicado: (2019)

1946. In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population
por: Bryson-Cahn, Chloe, et al.
Publicado: (2019)

2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

In Vitro Activity of Dalbavancin against Refractory Multidrug-Resistant (MDR) Staphylococcus aureus Isolates
por: Bongiorno, Dafne, et al.
Publicado: (2020)

Methicillin-Susceptible Staphylococcus aureus in Skin and Soft Tissue Infections, Northern Italy
por: Tinelli, Marco, et al.
Publicado: (2009)

The antimicrobial activity of ceftobiprole against Methicillin-resistant Staphylococcus aureus and multi-drug resistant Pseudomonas aeruginosa : A large tertiary care university hospital experience in Riyadh, Saudi Arabia
por: Altamimi, Lamees A., et al.
Publicado: (2022)

Serpins in Tick Physiology and Tick-Host Interaction
por: Abbas, Muhammad Nadeem, et al.
Publicado: (2022)

The application of machine learning to imaging in hematological oncology: A scoping review
por: Kotsyfakis, Stylianos, et al.
Publicado: (2022)

Methicillin-Resistant Staphylococcus aureus
por: Tenover, Fred C., et al.
Publicado: (2004)

Methicillin-Resistant Staphylococcus Aureus
por: Al-Quorain, Abdulaziz
Publicado: (2016)

Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial
por: Hamed, Kamal, et al.
Publicado: (2020)

2532. Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with Staphylococcus aureus Bacteremia
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

Safety and tolerability of ceftobiprole
por: Grau, Santiago
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_epncbl39nnll1efgvdi04rhjjd